title: [Efficacy and acceptability of dexfenfluramine in women consulting in gynecology. 336 overweight patients treated for 3 months].
abstract: The efficacy on bodyweight and the acceptability of a three month treatment with dexfenfluramine (Isoméride), combined with a prescribed diet, were evaluated in 336 women followed by a gynecologist for overweight. These women were divided into three groups, those in the sexually active age group (80%) and perimenopausal and post-menopausal women (20%) and had the following characteristics: mean bodyweight 80.2 +/- 0.6 kg; excess bodyweight 35.0 +/- 0.5% of theoretical ideal weight, mean bodyweight index = 30.6 +/- 0.2 kg/m2. Simultaneously with the weight loss, a study of the change in gynecological symptoms was carried out at each consultation and for each group. Investigation of the bodyweight showed that 80% of the patient who followed the treatment for three months lost weight, the mean loss being 7.2 kg or 41.9% of the initial excess weight. Simultaneously with this loss of weight, there was an improvement in the gynecological symptoms in all three groups. These symptoms included those seen in the premenstrual phase (sexually active age group) and menopause-related symptoms in the perimenopausal and post menopausal groups. The acceptability and safety of Isomeride were also confirmed in this study.
authors.affiliation: Gynécologue, Responsable du Centre Ménopause, Paris.
authors.forename: D
authors.initials: D
authors.lastname: Elia
authors.forename: J
authors.initials: J
authors.lastname: Auclair
authors.forename: C
authors.initials: C
authors.lastname: Rey
mesh_terms: D000328:Adult; D005260:Female; D005277:Fenfluramine / Q000008:administration & dosage*; D005831:Genital Diseases, Female / Q000188:drug therapy; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D011293:Premenstrual Syndrome / Q000188:drug therapy; D012449:Safety; D013997:Time Factors
chemical_list: D005277:Fenfluramine
vernacular_title: Etude de l'efficacité et de l'acceptabilité de la dexfenfluramine chez des femmes consultant en gynécologie. 336 patientes en excès de poids traitées trois mois.